经验

Luqa Ventures Sells to CMS

February 2, 2021

Cooley advised Luqa Ventures, a dermatology specialty company, on its sale of all issued and outstanding shares to China Medical System (0867.HK). Following the transaction, Luqa became a wholly-owned subsidiary of CMS. Luqa has an extensive portfolio of prescription medicines, medical devices, medical aesthetic solutions and skin care products that meets the diversified needs of consumers in China and provides the market with safe and effective solutions for a broad range of skin conditions. This acquisition marked CMS’s first foray into the medical aesthetic market. Partner James Lu led the Cooley team advising Luqa Ventures on the transaction.

Related contacts

沈亨达
顾问律师, 上海

Related Practices & Industries

Hello Group Acquires Happn

September 24, 2025

Cooley advised Hello Group, a leading player in Asia’s online social networking space, on its acquisition of Happn, a French location-based social search mobile and web application that enables users to connect with others based on their proximity and interests.

Read more

Related contacts

徐一林
合伙人, 北京
蔡华
合伙人, 香港
李若木
合伙人, 上海
沈亨达
顾问律师, 上海
苏伦嘎
律师, 上海
Bartholomäus Regenhardt
Associate, 布鲁塞尔
Patrick Van Eecke
合伙人, 布鲁塞尔
Charles Haley
Partner, 帕罗奥图
Hardy Zhou
Associate, 纽约
Athina Gaki
Associate, 布鲁塞尔
Julie Paulino Montejo
Associate, 纽约
Len Jacoby
Partner, 纽约
Christopher Kimball
Partner, 华盛顿特区
John Paul Oleksiuk
Partner, 纽约
Sharon Connaughton
Special Counsel, 华盛顿特区
Dillon Martinson
Special Counsel, 华盛顿特区
Yi Jia Ng
Special Counsel, 新加坡
Anna Caro
Associate, 伦敦
Michael Pelle
Associate, 纽约
姚植洪
律师, 香港
Veronica Cortes
Paralegal Specialist, 纽约

Related Practices & Industries

AusperBio Secures $63 Million Series B2

September 21, 2025

Cooley advised AusperBio, a privately held, clinical-stage biotechnology company dedicated to advancing targeted oligonucleotide therapies to achieve a functional cure for chronic hepatitis B (CHB), on its $63 million Series B2 financing.

Read more

Related contacts

Andrew Harline
Partner in Charge – Singapore, 新加坡
沈亨达
顾问律师, 上海
苏伦嘎
律师, 上海
Dr. Madhuri Roy
Partner, 帕罗奥图
魏 乐天
法律顾问, 上海

Related Practices & Industries

Ambiq Micro Announces Pricing of $96 Million IPO

July 30, 2025

Cooley advised Ambiq Micro, a technology leader in ultra-low-power semiconductor solutions for edge artificial intelligence, on its $96 million initial public offering (IPO).

Read more

Related contacts

Christina T. Roupas
Partner in Charge – Chicago, 芝加哥
Courtney M.W. Tygesson
Partner, 芝加哥
Michael Platt
Partner in Charge – Colorado, 科罗拉多
Kelly Bartling
Special Counsel, 科罗拉多
Grady Chang
Associate, 洛杉矶
Keith Berets
Partner, 科罗拉多
蔡华
合伙人, 香港
Annie Froehlich
Partner, 华盛顿特区
Austin Holt
Partner, 洛杉矶
Len Jacoby
Partner, 纽约
Christopher Kimball
Partner, 华盛顿特区
Kevin King
Partner, 华盛顿特区
陆培祥
合伙人, 新加坡
Barbara Mirza
Partner, 洛杉矶
Tim Pitrelli
Partner, 新加坡
Nicola Squire
Partner, 伦敦
Jeffrey J. Tolin
Partner, 纽约
Francis Wheeler
Senior Counsel, 科罗拉多
Mark Windfeld-Hansen
Senior Counsel, 帕罗奥图
Alaina DeBona
Special Counsel, 芝加哥
Andrew Epstein
Special Counsel, Seattle
Brooke Fritz
Special Counsel, 科罗拉多
Rebecca Ross
Special Counsel, 华盛顿特区
Vince Sampson
Special Counsel, 华盛顿特区
沈亨达
顾问律师, 上海
Karen Tsai
Special Counsel, 华盛顿特区
Blake Martell
Of counsel, 旧金山
Mateus Kaba Aboud
Associate, 芝加哥
Adam Bloom
Associate, 芝加哥
Umer Chaudhry
Associate, 华盛顿特区
Stefan Cohen
Associate, 纽约
Megan Drill
Associate, 圣地亚哥
Ryan Guo
Associate, 纽约
Sarah Oliai
Associate, 华盛顿特区
Samuel Paullin
Associate, 芝加哥
Taryn Wilkins
Associate, 芝加哥
Katherine Duplay
Paralegal Specialist, 科罗拉多
Alla Kagan
Paralegal Specialist, 圣地亚哥
Robin K. Lee
Paralegal Specialist, 科罗拉多
Brian Youn
Paralegal Specialist, 帕罗奥图
Brian Mitchell
Transactional Quantitative Analyst, 圣地亚哥

Related Practices & Industries

InnoCare and KeyMed Jointly Announce License Agreement With Prolium

January 20, 2025

Cooley represented Beijing Tiannuo Jiancheng Pharmaceutical Technology, a joint venture of a subsidiary of InnoCare Pharma (HKEX: 09969; SSE: 688428) and a subsidiary of KeyMed Biosciences (HKEX: 02162), in connection with a joint exclusive license agreement with Prolium Bioscience for the development and commercialization of ICP-B02 (CM355), a CD20xCD3 bispecific antibody.

Read more

Related contacts

Lila Hope
Partner, 帕罗奥图
叶明晖
律师
沈亨达
顾问律师, 上海
汪晨
律师, 上海
魏 乐天
法律顾问, 上海
Jameson Davis
Associate, 波士顿
Robert Eisenbach
Of Counsel, 旧金山
王滨
资深顾问, 帕罗奥图
徐璨
顾问律师, 上海

Related Practices & Industries

查看全部

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.